Clinical experience with abiraterone acetate application in patients with castration-resistant prostate cancer
- Authors: Gridneva Y.V1, Matveev VB1, Kupchan DZ1, Kalinin SA2, Peters MV3
-
Affiliations:
- ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
- ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России, Москва
- ГБОУ ДПО РМАПО Минздрава России, Москва
- Issue: Vol 16, No 3 (2014)
- Pages: 94-96
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26988
- ID: 26988
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Ya V Gridneva
ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москваканд. мед. наук, врач отд-ния урологии
V B Matveev
ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москвад-р мед. наук, проф., зав. отд-нием урологии
D Z Kupchan
ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москварук. отд-ния организации и проведения клинических исследований
S A Kalinin
ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России, Москваассистент каф. онкологии и лучевой терапии
M V Peters
ГБОУ ДПО РМАПО Минздрава России, Москваассистент каф. онкологии
References
- Hellerstedt B.A, Pienta K.J. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002; 52: 154-79.
- Snoek R, Cheng H, Margiotti K et al. In vivo knockdown of the Androgen Receptor Results in Growth Inhibition and Regression of Well-Established, Castration-Resistant Prostate Tumors. Clin Cancer Res 2009; 15: 39-47.
- Scher H.I, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-59.
- Tannock I.F, De Wit R, Berry W.R et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.
- Petrylak D.P, Tangen C.M, Hussain M.H et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20.
- Saad F, Gleason D.M, Murray R et al. A randomized, placebo - controlled trial of zoledronic acid in patients with hormone - refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-68.
- Sternberg C.N, Petrylak D.P, Sartor O et al. Multinational, double - blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate - refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27: 5431-8.
- Engel-Nitz N.M, Alemayehu B, Parry D, Nathan F. Differences in treatment patterns among patients with castration - resistant prostate cancer treated by oncologists versus urologists in a US managed care population. Cancer Manag Res 2011; 3: 233-45.
- Harris V, Lloyd K, Forsey S, Rogers P, Roche M, Parker C. A population - based study of prostate cancer chemotherapy. Clin Oncol (R Coll Radiol) 2011; 23: 706-8.
- Kantoff P.W, Higano C.S, Shore N.D et al. Sipuleucel-T immunotherapy for castration - resistant prostate cancer. N Engl J Med 2010; 363: 411-22.
- Mottet N et al. Guidelines on prostate cancer. Eur Urol 2014; 65 (1): 124-37; Eur Urol 2014; 65 (2): 467-79.
- Berthold D.R et al. Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival Analysis in the TAX 327 study. J Clin Oncol 2008; 26: 242-5.
- Attard G, Reid A.H, A’Hern R et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration - resistant prostate cancer. J Clin Oncol 2009; 27: 3742-8.
- Attard G, Reid A.H, De Bono J.S. Abiraterone acetate is well tolerated without concomitant use of corticosteroids. J Clin Oncol 2010; 28 (29): e560-e561.
- Attard G, Reid A.H, Yap T.A et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration - resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26: 4563-71.
- Danila D.C, Morris M.J, De Bono J.S et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel - treated castration - resistant prostate cancer. J Clin Oncol 2010; 28:1496-501.
- Reid A.H, Attard G, Danila D.C et al. Significant and sustained antitumor activity in post docetaxel, castration - resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28:1489-95.
- Ryan C.J, Smith M.R, Fong L et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration - resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28:1481-8.
- De Bono J.S, Logothetis C.J, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
- Fizazi K, Scher H.I, Molina A. Abiraterone acetate for treatment of metastatic castration - resistant prostate cancer: final overall survival analysis of the COU- AA-301 randomised, double - blind, placebo - controlled phase 3 study. Lancet Oncol 2012; 13 (Issue 10): 983-99.
- Ryan C.J, Smith M.R, De Bono J.S. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. N Engl J Med 2013; 368 (2): 138-48.
- Jr Goodman O.B et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration - resistant cancer. Prostate Cаncer Prostatic Dis 2014; 17: 34-9.
- Rathkopf D.E. Genitourinary Cancers Symposium. J Clin Oncol 2013; 31 (Suppl. 6): 5.